Gesynta Pharma Ab

Gesynta Pharma Ab company information, Employees & Contact Information

Gesynta Pharma's drug candidate vipoglanstat (GS-248) is in clinical phase II development for the treatment of endometriosis – a painful, chronic inflammatory disease that affects about 10 percent of women of reproductive age. Endometriosis often leads to severely reduced quality of life, and current drug treatments are inadequate for many patients. Gesynta Pharma aims to exploit the full potential of microsomal prostaglandin E synthase-1 (mPGES-1) as a pharmacological target by developing products in areas of unmet medical need where mPGES-1 inhibition provides clear benefits compared to current therapy. Gesynta Pharma’s second drug candidate to reach clinical development, GS-073, has the same mode of action as vipoglanstat. GS-073 is ready to enter clinical phase I for the treatment of chronic inflammatory pain. Gesynta Pharma bases its R&D on research from the Karolinska Institutet. Major shareholders include Industrifonden, Hadean Ventures, Linc, and a number of successful life science entrepreneurs.

Company Details

Employees
17
Founded
-
Address
Wallingatan 24, Stockholm,stockholm County 11124,sweden
Phone
559103-6628
Email
in****@****ynta.se
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
gesynta.se
HQ
Stockholm, Stockholm County
Looking for a particular Gesynta Pharma Ab employee's phone or email?

Gesynta Pharma Ab Questions

News

Gesynta Pharma Receives $27 M For Endometriosis Novel Therapy Drug - Forbes

Gesynta Pharma Receives $27 M For Endometriosis Novel Therapy Drug Forbes

Gesynta Pharma Adds $3.9M in Series B Funding for Endometriosis Drug, Total Round Reaches $31.5M - Femtech Insider

Gesynta Pharma Adds $3.9M in Series B Funding for Endometriosis Drug, Total Round Reaches $31.5M Femtech Insider

New Swedish Pharma Bids for Anti-Inflammatory Drugs Without Side Effects - Labiotech.eu

New Swedish Pharma Bids for Anti-Inflammatory Drugs Without Side Effects Labiotech.eu

€26.5M Series B funding pushes Swedish company's endometriosis therapy to next stage - ArcticStartup - ArcticStartup

€26.5M Series B funding pushes Swedish company's endometriosis therapy to next stage - ArcticStartup ArcticStartup

Gesynta Pharma presents mPGES1 inhibitor GS-248 for pain and inflammation - BioWorld MedTech

Gesynta Pharma presents mPGES1 inhibitor GS-248 for pain and inflammation BioWorld MedTech

FDA grants GS-248 orphan drug designation for systemic sclerosis - Healio

FDA grants GS-248 orphan drug designation for systemic sclerosis Healio

Top Gesynta Pharma Ab Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant